FTC wants to know: How are PBMs affecting drug affordability and access?

Following the Federal Trade Commission’s decision to not, at least initially, dig deeper into pharma middlemen known as PBMs, the commission is now seeking comments on ways that these massive, vertically integrated PBMs are affecting drug affordability and access.


Read the full story >